Charge-Reversed Exosomes Enable Cartilage-Targeted mRNA Deli
2026-06-20
Zhang et al. present a non-viral gene delivery platform using charge-reversed exosomes to transport mRNA efficiently into dense cartilage tissue for osteoarthritis therapy. Their approach overcomes longstanding barriers in intra-cartilage delivery, demonstrating robust mRNA penetration and expression in deep chondrocyte layers, with strong translational potential for targeted gene therapies.
Angiotensin II (A1042): Technical Guidance for Vascular Mode
2026-06-19
Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is a validated peptide tool for inducing vasoconstriction, hypertension, and vascular remodeling in experimental research. This product is best suited for cell-based and animal models requiring precise control of vascular responses but is not intended for diagnostic or clinical use.
Dual Glutamate Receptor Blockade Mitigates Soman-Induced Neu
2026-06-19
This study introduces a dual-targeting approach with IEM-1925 for blocking both AMPA and NMDA glutamate receptors, demonstrating robust protection against soman-induced status epilepticus and neurodegeneration in rats. The findings highlight significant advantages over standard therapies and underscore the translational potential of selective AMPA receptor blockers in acute neurotoxicity research.
Network Pharmacology Identifies Apigenin for Alzheimer’s The
2026-06-18
A recent study employs a network medicine framework to systematically identify flavonoid candidates for Alzheimer’s disease (AD) therapy, highlighting Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) as a leading neuroprotective agent. Experimental validation demonstrates that Apigenin modulates apoptosis, neuroinflammation, and key signaling pathways, providing actionable targets for translational research.
Ultra Fast LC–MS/MS for Cefazedone & Etimicin: Pharmacokinet
2026-06-18
This study introduces an ultra fast liquid chromatography–tandem mass spectrometry (UFLC–MS/MS) method for the simultaneous quantification of cefazedone and etimicin in beagle dog plasma. The validated protocol enabled the first detailed pharmacokinetic comparison between combined and single-agent administration, revealing no significant pharmacokinetic interactions and supporting rational combination therapy.
HyperScribe™ Poly (A) Tailing Kit: Enhancing mRNA Stability
2026-06-17
The HyperScribe™ Poly (A) Tailing Kit enables robust polyadenylation of RNA using E. coli Poly (A) Polymerase, supporting improved mRNA stability and translation efficiency. This reagent set is engineered for research workflows requiring reproducible, high-quality in vitro RNA modification, particularly for transfection and gene expression studies.
Vancomycin for Bacterial Resistance: Mechanisms and Assay Im
2026-06-17
Explore the scientific depth of Vancomycin, a glycopeptide antibiotic, focusing on its cell wall synthesis inhibition and the critical role it plays in advanced resistance research. This article uniquely bridges molecular mechanisms with practical assay decisions, offering insights beyond standard guides.
MLN2238 and the CRTC-CREB Axis: A New Era for Proteasome Inh
2026-06-16
Discover how MLN2238 is redefining proteasome inhibition in translational oncology, integrating mechanistic insights on the CRTC-CREB axis, ROS/JNK signaling, and redox-driven stress responses to empower researchers in multiple myeloma and lymphoma.
DAMGO as a Precision µ-Opioid Receptor Agonist in Pain Model
2026-06-16
DAMGO stands out as a gold-standard µ-opioid receptor agonist, enabling precise dissection of opioid signaling and analgesia. Its high selectivity and reproducible performance empower advanced studies on pain pathways, hypersensitivity, and tolerance.
EPI-001: Androgen Receptor N-Terminal Domain Inhibitor in Ca
2026-06-15
EPI-001 offers a unique mechanism for inhibiting both full-length AR and resistant ARv7 variants, directly targeting the androgen receptor N-terminal domain. This enables advanced research into prostate cancer, castration-resistant disease, and AR-driven triple-negative breast cancer, with robust protocol guidance and troubleshooting strategies.
CD47 Blocks Phagocytosis via Vav Dephosphorylation and Rac1
2026-06-15
This study elucidates the molecular mechanism by which CD47 inhibits macrophage-mediated phagocytosis, revealing that CD47 engagement prevents Vav phosphorylation and suppresses Rac1-driven cytoskeletal remodeling. These insights clarify how healthy cells evade immune clearance and highlight new intervention points within the Rac1 signaling pathway relevant to cancer immunotherapy.
Applied mRNA Delivery: EZ Cap™ Cy5 EGFP mRNA (5-moUTP) in Ac
2026-06-14
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) empowers researchers with real-time, dual-fluorescent tracking of both mRNA uptake and translation, streamlining assay optimization and immune-evasive gene delivery studies. Discover how this APExBIO reagent integrates advanced modifications for robust, reproducible mRNA workflows across cell types.
HCMV-Mediated AKT Inactivation via IRS1 Destabilization Mech
2026-06-13
This study uncovers how human cytomegalovirus (HCMV) inactivates AKT by triggering degradation of insulin receptor substrate 1 (IRS1) through the viral protein UL38 and mTORC1 activation. These findings clarify a unique viral strategy for remodeling host PI3K/AKT signaling, with critical implications for understanding virus-host interactions and phosphoproteomic study design.
Triiodothyronine (T3) in Cellular Metabolism and Signaling A
2026-06-12
Triiodothyronine (T3) transforms thyroid hormone signaling pathway research with high-purity, reproducible modulation of metabolic and gene regulatory processes. Discover protocol refinements, troubleshooting strategies, and cutting-edge applications that leverage APExBIO’s T3 for advanced cellular metabolism and disease modeling.
L-Phenylephrine: Precision Control in α1A Adrenergic Researc
2026-06-12
Explore how L-Phenylephrine, a selective adrenergic α1A receptor agonist, enables advanced dissection of cardiovascular and neural signaling. This article delivers a unique perspective on integrating sex-difference data and molecular assay design for research innovation.
466 records 15/32 page Previous Next First page 上5页 1112131415 下5页 Last page